

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

AGE/ GENDER : 73 YRS/Male PATIENT ID : 1740993

COLLECTED BY: SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 31/Jan/2025 01:50 PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

# HAEMATOLOGY GLYCOSYLATED HAEMOGLOBIN (HBA1C)

GLYCOSYLATED HAEMOGLOBIN (HbA1c): 6 % 4.0 - 6.4

WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

ESTIMATED AVERAGE PLASMA GLUCOSE 125.5 mg/dL 60.00 - 140.00

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

#### **INTERPRETATION:**

AS PER AMERICAN DI	ABETES ASSOCIATION (ADA):	
REFERENCE GROUP	GLYCOSYLATED HEMOGL	OGIB (HBAIC) in %
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.4	
Diagnosing Diabetes	>= 6.5	
	Age > 19 Y	ears
Therapeutic goals for glycemic control	Goals of Therapy:	< 7.0
	Actions Suggested:	>8.0
	Age < 19 Y	ears
	Goal of therapy:	<7.5

#### COMMENTS:

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

  4. High
- HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications
- 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.
- 6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.
- 7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

**AGE/ GENDER** : 73 YRS/Male **PATIENT ID** : 1740993

COLLECTED BY : SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

**CLIENT CODE.** : KOS DIAGNOSTIC LAB **REPORTING DATE** : 31/Jan/2025 01:50PM


**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### LIFOTRONIC Graph Report

Name :	Case:	Patient Type :	Test Date: 31/01/2025 16:10:33
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: 01524714
Gender:			Total Area: 9368

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	70	2579	8279	83.1
HbA1c	37	59	599	6.0
La1c	26	34	241	2.4
HbF	18	15	23	0.2
Hba1b	14	34	131	1.3
Hba1a	11	25	95	0.9





DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana
KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana
0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

AGE/ GENDER : 73 YRS/Male PATIENT ID : 1740993

COLLECTED BY: SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 31/Jan/2025 03:57 PM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

### CLINICAL CHEMISTRY/BIOCHEMISTRY LIVER FUNCTION TEST (COMPLETE)

BILIRUBIN TOTAL: SERUM by DIAZOTIZATION, SPECTROPHOTOMETRY	0.5	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
BILIRUBIN DIRECT (CONJUGATED): SERUM by DIAZO MODIFIED, SPECTROPHOTOMETRY	0.11	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM by CALCULATED, SPECTROPHOTOMETRY	0.39	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	17.3	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	9.2	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.88	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM by Para nitrophenyl phosphatase by amino methyl propanol	83.27	U/L	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by SZASZ, SPECTROPHTOMETRY	16.67	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by biuret, spectrophotometry	7.44	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by Bromocresol green	4.55	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.89	gm/dL	2.30 - 3.50
A: GRATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.57	RATIO	1.00 - 2.00

#### **INTERPRETATION**

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

USE:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

### INCREASED:

MORE/IGED.	
DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

AGE/ GENDER : 73 YRS/Male PATIENT ID : 1740993

COLLECTED BY : SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

**CLIENT CODE.** : KOS DIAGNOSTIC LAB **REPORTING DATE** : 31/Jan/2025 03:57PM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS		> 1.3 (Slightly Increased)	

**DECREASED:** 

- 1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)
- 2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

#### PROGNOSTIC SIGNIFICANCE:

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana
KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana
0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

**AGE/ GENDER** : 73 YRS/Male **PATIENT ID** : 1740993

COLLECTED BY: SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 31/Jan/2025 03:57 PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

**UREA** 

UREA: SERUM 27.28 mg/dL 10.00 - 50.00

by UREASE - GLUTAMATE DEHYDROGENASE (GLDH)

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Dr. ARUN WALIA

**AGE/ GENDER** : 73 YRS/Male **PATIENT ID** : 1740993

COLLECTED BY : SURJESH REG. NO./LAB NO. : 012501310040

 REFERRED BY
 : 31/Jan/2025 12:19 PM

 BARCODE NO.
 : 01524714
 COLLECTION DATE
 : 31/Jan/2025 12:22 PM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 31/Jan/2025 03:57 PM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

**CREATININE** 

CREATININE: SERUM 1.09 mg/dL 0.40 - 1.40 by ENZYMATIC, SPECTROPHOTOMETRY

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Dr. ARUN WALIA

**AGE/ GENDER** : 73 YRS/Male **PATIENT ID** : 1740993

**COLLECTED BY** : SURJESH REG. NO./LAB NO. :012501310040

REFERRED BY **REGISTRATION DATE** : 31/Jan/2025 12:19 PM BARCODE NO. **COLLECTION DATE** : 31/Jan/2025 12:22PM :01524714 CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 31/Jan/2025 02:17PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

### TUMOUR MARKER PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL

PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL: 0.3 ng/mL 0.0 - 4.0

**SERUM** 

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

#### INTERPRETATION:

#### NOTE:

- 1. This is a recommended test for detection of prostate cancer along with Digital Rectal Examination (DRE) in males above 50 years of age.
- 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- 3. PSA levels may appear consistently elevated / depressed due to the interference by heterophilic antibodies & nonspecific protein binding 4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massage, indwelling catheterization, ultrasonography and needle biopsy of prostate is not recommended as they falsely elevate levels
- 5. PSA values regardless of levels should not be interpreted as absolute evidence of the presence or absence of disease. All values should be correlated with clinical findings and results of other investigations
- 6. Sites of Non-prostatic PSA production are breast epithelium, salivary glands, peri-urethral & anal glands, cells of male urethra & breast milk 7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity
- 8. The concentration of PSA in a given specimen, determined with assays from different manufacturers, may not be comparable due to differences in assay methods, calibration, and reagent specificity.

### RECOMMENDED TESTING INTERVALS

- 1. Preoperatively (Baseline)
- 2. 2-4 Days Post operatively
- 3. Prior to discharge from hospital

Monthly Follow I In if levels are high and showing a rising trend

POST SURGERY	FREQUENCY OF TESTING	
1st Year	Every 3 Months	
2 <sup>nd</sup> Year	Every 4 Months	
3 <sup>rd</sup> Year Onwards	Every 6 Months	

#### **CLINICAL USE:**

- 1. An aid in the early detection of Prostate cancer when used in conjunction with Digital rectal examination in males more than 50 years of age and in those with two or more affected first degree relatives.
- 2. Followup and management of Prostate cancer patients.
- 3. Detect metastatic or persistent disease in patients following surgical or medical treatment of Prostate cancer

### **INCREASED LEVEL:**

- 1. Prostate cancer
- 2. Benign Prostatic Hyperplasia
- 3. Prostatitis
- 4. Genitourinary infections



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



CLIENT CODE.

# KOS Diagnostic Lab (A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

: 31/Jan/2025 02:17PM

: Dr. ARUN WALIA **NAME** 

**AGE/ GENDER PATIENT ID** :1740993 : 73 YRS/Male

**COLLECTED BY** : SURJESH : 012501310040 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 31/Jan/2025 12:19 PM **COLLECTION DATE** BARCODE NO. :01524714 : 31/Jan/2025 12:22PM

: KOS DIAGNOSTIC LAB **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name Value** Unit **Biological Reference interval** 

REPORTING DATE

End Of Report



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com